Insider Transactions in Q3 2023 at Surface Oncology, Inc. (SURF)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 08
2023
|
Alison Oneill Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
56,686
-100.0%
|
-
|
|
Sep 08
2023
|
David S. Grayzel Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,945,453
-100.0%
|
-
|
|
Sep 08
2023
|
Robert W. Ross Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
83,193
-100.0%
|
-
|
|
Sep 08
2023
|
Jessica Fees Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
101,915
-100.0%
|
-
|
|
Sep 08
2023
|
Jeff Goater Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
129,222
-100.0%
|
-
|
|
Sep 08
2023
|
Vito J. Palombella Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
87,212
-100.0%
|
-
|
|
Sep 08
2023
|
Henry C. Rath Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
44,971
-100.0%
|
-
|
|
Sep 08
2023
|
Chandra Adams Deputy GC |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,884
-100.0%
|
-
|
|
Sep 08
2023
|
Charles Elliott Sigal Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
45,453
-100.0%
|
-
|
|
Aug 01
2023
|
Robert W. Ross Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,713
-16.73%
|
$0
$0.94 P/Share
|
|
Aug 01
2023
|
Alison Oneill Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,042
-11.05%
|
$0
$0.94 P/Share
|
|
Aug 01
2023
|
Jessica Fees Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,434
-8.47%
|
$0
$0.94 P/Share
|
|
Aug 01
2023
|
Chandra Adams Deputy GC |
SELL
Open market or private sale
|
Direct |
3,901
-11.21%
|
$0
$0.94 P/Share
|